Sangui Financial Statements From 2010 to 2024
| SGBI Stock | USD 0 0.00 0.00% |
Check Sangui Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sangui Biotech's main balance sheet or income statement drivers, such as , as well as many indicators such as . Sangui financial statements analysis is a perfect complement when working with Sangui Biotech Valuation or Volatility modules.
Sangui |
Sangui Biotech International Company Return On Asset Analysis
Sangui Biotech's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Sangui Biotech Return On Asset | -0.64 |
Most of Sangui Biotech's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sangui Biotech International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Sangui Biotech International has a Return On Asset of -0.6411. This is 92.67% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on asset for all United States stocks is notably higher than that of the company.
Sangui Biotech Inter Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sangui Biotech's current stock value. Our valuation model uses many indicators to compare Sangui Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sangui Biotech competition to find correlations between indicators driving Sangui Biotech's intrinsic value. More Info.Sangui Biotech International is rated fourth in return on asset category among its peers. It is rated second in profit margin category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Sangui Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Sangui Biotech's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Sangui Biotech Financial Statements
Investors use fundamental indicators, such as Sangui Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Although Sangui Biotech's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany. Sangui Biotech is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Sangui Pink Sheet
Sangui Biotech financial ratios help investors to determine whether Sangui Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sangui with respect to the benefits of owning Sangui Biotech security.